Tesamorelin is a synthetic growth hormone releasing hormone analogue, commonly described as a 44 amino acid peptide analogue of GHRH. It is best known for its FDA approved use in HIV associated lipodystrophy, where clinical data have reported selective reductions in visceral abdominal fat while preserving subcutaneous fat.
That makes Tesamorelin one of the more specific peptides discussed in relation to abdominal fat distribution. The key point is selectivity. Tesamorelin is not usually framed around general weight loss. It is most often discussed for visceral fat, the deeper abdominal fat stored around organs, and for its effect on endogenous growth hormone signalling.
What Tesamorelin is used for in research
Tesamorelin is a Human Growth Hormone Releasing Factor (1-44) analogue. It is designed to stimulate the body’s own growth hormone release through GHRH receptor activity rather than acting as growth hormone itself.
Its strongest established clinical context is HIV associated lipodystrophy. In that setting, it has been associated with a 15 to 20% reduction in visceral fat in clinical trials. The reference profile also notes preserved subcutaneous fat, which is one reason Tesamorelin is treated differently from broader fat loss compounds.
Beyond that approved indication, Tesamorelin is often discussed in research contexts involving GH stimulation, body composition, lipid markers, liver fat and cognitive function. These areas should not be treated as interchangeable with approved medical use.
How Tesamorelin targets visceral fat
Tesamorelin works by stimulating the pituitary gland to increase pulsatile growth hormone release. This raises downstream signalling, including IGF-1, and is associated with changes in fat metabolism.
The mechanism is often contrasted with shorter GHRH fragments. Tesamorelin is described as a stable, full length analogue, which helps explain why it has become a reference point in discussions about selective visceral fat reduction.
The research profile describes subcutaneous administration as providing bioavailability for GHRH receptor binding and pulsatile GH release stimulation. In clinical and research discussions, this is tied to selective targeting of visceral adipose tissue while sparing subcutaneous fat.
Visceral fat, liver fat and metabolic markers
The main body composition finding linked to Tesamorelin is visceral abdominal fat reduction. The reference profile cites 15 to 20% visceral fat reduction in clinical trials for HIV associated lipodystrophy.
Tesamorelin is also discussed in relation to liver fat. The supplied research profile notes a 37% liver fat reduction over 12 months in NAFLD related research. This does not make Tesamorelin a general recommendation for fatty liver disease, but it explains why the compound appears in metabolic research discussions.
Other metabolic markers in the profile include a 12.3% reduction in triglyceride levels and a 7.2% improvement in cholesterol markers. These figures are useful for understanding the research interest around Tesamorelin, although they should be read in the context of the studied populations and protocols.
Body composition and lean mass preservation
Tesamorelin is often positioned around selective fat distribution rather than simple scale weight. The profile notes lean mass preservation during fat loss, with IGF-1 elevation listed as a moderate body composition effect.
IGF-1 increase is part of the reason Tesamorelin requires careful monitoring in clinical contexts. The reference data reports a 26% increase in IGF-1 levels, and also notes that 47% of subjects exceeded the normal range at 26 weeks. That is a meaningful safety consideration, not a minor laboratory detail.
Cognitive and inflammatory pathways
Tesamorelin is sometimes discussed beyond fat metabolism because growth hormone signalling affects multiple systems. The supplied material refers to potential reductions in neuroinflammation and possible improvement in executive memory.
These areas are better viewed as exploratory or context dependent rather than settled consumer benefits. They help explain why researchers are interested in Tesamorelin, but they should not be presented as guaranteed cognitive enhancement.
What the research timeline tends to look like
The reference profile gives a staged view of how Tesamorelin effects may appear under studied conditions. Early changes involve signalling markers rather than visible body composition shifts.
Period Reported research observations
Week 1 to 3 - 2IGF-1 levels begin to rise. Mild water retention or joint discomfort may occur.
Week 4 to 6 - Early metabolic changes may be observed, with some reports of improved energy or sleep.
Week 8 to 12 - Visible visceral fat reduction may begin, and waist circumference may decrease.
Week 12 to 26 - Peak body composition changes are typically reported in the supplied profile.
This timeline should not be read as a dosing plan or a personal outcome forecast. It is a summary of the research profile supplied for the compound. PeptideSupermarket® Research Tesamorelin
Safety signals and contraindications
Tesamorelin is not a casual fat loss peptide. Its GH and IGF-1 effects are exactly why safety monitoring matters.
Commonly listed side effects include injection site reactions, joint pain and water retention. The reference profile reports injection site reactions at 17% and joint pain at 13%. The source material also highlights fluid retention and carpal tunnel type symptoms as concerns.
More serious stop signs include development of diabetes or severe glucose intolerance, signs of malignancy, severe hypersensitivity reactions and excessive IGF-1 elevation with acromegaly symptoms. The profile specifically flags HbA1c of 6.5% or higher as a severe glucose intolerance concern and notes a 3.3 fold increased diabetes risk.
Contraindications in the reference profile include active malignancy, pituitary disorders and pregnancy. The concern around malignancy is particularly important because GH and IGF-1 pathways can be relevant to growth signalling.
Tesamorelin’s clinical specificity is part of its appeal, but the same endocrine activity that makes it interesting also makes unsupervised use risky.
Why access and cost are often discussed
Tesamorelin is FDA approved for a narrow indication, HIV associated lipodystrophy. That limited regulatory positioning is one reason it can be difficult to access outside that context.
The branded product has also been described as expensive, with the supplied material noting a cost of around $6,000. For South African readers researching peptides SA, this is one reason price comparison and supplier transparency matter, especially where products are listed strictly for laboratory research. PeptideSupermarket® Research Tesamorelin
PeptideSupermarket®’s peptide price comparison page compares research peptides and related compounds. It does not sell, supply or ship products, and listings should not be interpreted as approval for human or animal use.
How to assess Tesamorelin listings in South Africa
For anyone comparing a peptide supplier SA, the first question should be whether the product is clearly positioned for in vitro laboratory research. Avoid listings that make unsupported medical promises, give casual self administration instructions or present Tesamorelin as a guaranteed route to fat loss.
Useful comparison points include product identity, stated purity testing, batch information, supplier transparency, pricing and whether the listing avoids inappropriate treatment claims. Cheap peptides are not automatically good value if the supplier cannot support basic quality and compliance information.
For readers asking where to buy peptides for research comparison purposes, the safer approach is to compare multiple suppliers side by side instead of relying on a single listing or marketing claim.
Frequently asked questions
What is Tesamorelin?
Tesamorelin is a synthetic GHRH analogue, also known as a Human Growth Hormone Releasing Factor (1-44) analogue. It stimulates endogenous growth hormone release and is best known for its FDA approved use in HIV associated lipodystrophy.
Does Tesamorelin reduce visceral fat?
In the supplied research profile, Tesamorelin is associated with 15 to 20% visceral fat reduction in clinical trials for HIV associated lipodystrophy. It is described as selectively targeting visceral fat while preserving subcutaneous fat.
Is Tesamorelin the same as growth hormone?
No. Tesamorelin is a GHRH analogue that stimulates the body’s own growth hormone release. It is not growth hormone itself.
What are the main Tesamorelin side effects?
Commonly listed effects include injection site reactions, joint pain and water retention. More serious concerns include glucose intolerance, excessive IGF-1 elevation, hypersensitivity reactions and risks related to malignancy history.
Is Tesamorelin approved for general fat loss?
The supplied profile identifies Tesamorelin as FDA approved for HIV associated lipodystrophy. It should not be presented as a general fat loss treatment or a recommendation for self use.
Where can South African researchers compare Tesamorelin prices?
You can compare listed research peptide suppliers and pricing on the PeptideSupermarket®’s peptide price comparison page The site is for research peptide comparison and education, not for medical advice or product supply.
Research disclaimer
This content is for research and educational purposes only. It is not medical advice, does not recommend human or animal use, and should not be used to diagnose, treat, cure or prevent any disease.
Final view on Tesamorelin and visceral fat
Tesamorelin has stronger clinical grounding than many peptides discussed for body composition, especially because of its FDA approved role in HIV associated lipodystrophy and its reported 15 to 20% visceral fat reduction in that context. Its metabolic and liver fat profile also explains why it attracts research interest.
The same profile brings real cautions: IGF-1 elevation, glucose monitoring, water retention, joint symptoms and contraindications such as active malignancy or pituitary disorders. Tesamorelin should be understood as a tightly defined research and clinical compound, not a casual shortcut.
To compare current South African research listings and find the best value option, visit the PeptideSupermarket® price comparison page at PeptideSupermarket®’s peptide price comparison page
Compare Tesamorelin prices across the UK
Side-by-side prices from every trusted UK supplier stocking Tesamorelin.